Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 11%

Bulls say

Dynavax Technologies Corp has reported significant growth in its HEPLISAV-B sales, achieving a 39% year-over-year increase in the fourth quarter of 2024 and a 26% increase for the full year, totaling $268.4 million. The company has successfully expanded its market share to approximately 44% by the end of 2024, with expectations to capture at least 60% of a projected hepatitis B vaccination market exceeding $900 million by 2030. Further, Dynavax anticipates double-digit annual sales growth for HEPLISAV-B through 2030, fueled by increased penetration into the eligible adult population and re-vaccination practices.

Bears say

Dynavax Technologies faces significant challenges that contribute to a negative outlook for its stock, primarily due to the inherent risks associated with its product candidates, which may fail to meet efficacy or safety standards necessary for approval and commercialization. Additionally, the company struggles with the potential inability to effectively commercialize its products due to market dynamics, strong competition, and potential internal factors, which could impede its growth. Furthermore, notwithstanding a modest revenue report for Q4 2024, Dynavax has a history of financial losses and lacks a proven track record of profitability, heightening the uncertainty around its future performance.

Dynavax Technologies (DVAX) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Buy based on their latest research and market trends.

According to 9 analysts, Dynavax Technologies (DVAX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.